Snehal Bhoola, M.D.

Snehal Bhoola, M.D., joined City of Hope^® in 2023. As a gynecologic oncologist, Dr. Bhoola focuses his practice on the diagnosis and management of all types and stages of gynecologic malignancies, including ovarian, cervical, uterine, endometrial and vulvar, with a special focus on novel therapies for ovarian cancer and cervical cancer prevention. Having performed over 3,500 robotic surgeries, Dr. Bhoola is an expert in the surgical management of gynecologic malignancies. Dr. Bhoola works with a multidisciplinary team of subspecialists, providing all aspects of cancer care to women with gynecologic malignancies from diagnosis through survivorship. 

After earning his medical degree from Emory University School of Medicine, Dr. Bhoola completed a residency in obstetrics and gynecology at Vanderbilt University. During his residency he rotated as a distinguished Felix Rutledge Fellow at MD Anderson Cancer Center in Houston. He then completed his fellowship in gynecologic oncology at the University of Alabama. 

Dr. Bhoola is a member of several professional organizations, including American College of Obstetricians and Gynecologists, Society of Gynecologic Oncology, American College of Surgeons and the Phoenix Obstetrics and Gynecology Society and has been included on Phoenix Magazine’s list of Top Docs 2011-2013; 2015-2024. 

As a physician-researcher, he has published peer- reviewed studies covering a number of topics, including innovative treatments for ovarian cancer. Dr. Bhoola joined City of Hope in large part because of the institution’s reputation for compassionate, patient-centered care and innovative clinical trials

• 2011-2013, 2015-2023, Top Docs, Phoenix Magazine 
• 2014, Department of Obstetrics and Gynecology, Banner Good Samaritan Medical Center, CREOG National Faculty Award in Resident Education 
• Department of Obstetrics and Gynecology, Banner Good Samaritan Medical Center, CREOG National Faculty Award in Resident Education
• 2006, Department of Obstetrics and Gynecology, Mercer University School of Medicine, APGO National Award for Excellence in Medical Student Teaching 
• 2005, Department of Obstetrics and Gynecology, Mercer University School of Medicine, CREOG National Faculty Award in Resident Education 
• 2003, Department of Obstetrics and Gynecology, University of Alabama at Birmingham, Argus Award for Excellence in Medical Student Education 
• 2000 - 2001, Department of Obstetrics and Gynecology, Vanderbilt University, Administrative Chief Resident 
• 1998 - 2001, Ob/Gyn Resident Selection Committee 
• Department of Obstetrics and Gynecology, Emory University
• 1997, Award for Outstanding Medical Student Education, Emory University
• 1993, Summa Cum Laude graduate in Biology 
• 1992, Phi Beta Kappa

• Monk BJ, Colombo N, Oza A, Fukiwara K, Birrer M, Randall L, Poddubskaya E, Scambi G, Shparyk YV, Lim MC, Bhoola SM, Sohn J, Yonemori K, Stewart RA, Zhang X, Smith JP, Linn C, Ledermann J. Chemotherapy with or without avelumab followed by avelumab maintenance versus chemotherapy alone in patients with previously untreated epithelial ovarian cancer (JAVELIN Ovarian 100): an open- label, randomized, phase 3 trial. The Lancet Oncology. Sept 2021: 22 (9): 1275-1289.
• Bhoola SM, Burden of HPE and HPV Cancers, CME Oral Presentation, The American Academy of Pediatrics, Arizona Chapter, July 16, 2014.
• Liggins, Cassie, Bhoola SM. In-office removal of implanted subcutaneous venous catheter is safe feasible and cost-effective as compared to in-hospital removal. Oral presentation. MD Anderson Felix Rutledge Society Meeting, Phoenix AZ. May 14, 2014
• Gallup DG, Burke JJ II, Bhoola SM. An update on surgical incisions, wound closure and incisions. Contemp OB/Gyn, 2006; 51: 42-48.
• Bhoola, SM and Hoskins W. Diagnosis and Management of Epithelial Ovarian Cancer. Obstetrics and Gynecology, 2006;107: 1399-1410. 
• Kirby, TO, Rocconi RP, Numnum MT, Kendrick JE, Wright J, Fowler W, Mutch DG, Bhoola SM, Huh WK, Straughn Jr, JM. Outcomes of stage I/II vulvar cancer patients after negative superficial inguinal lymphadenectomy. Gynecologic Oncology, 2005; 98 (2): 309-312.
• Bhoola, SM. Is pegylated liposomal doxorubicin a superior second-line therapy for recurrent or persistent ovarian cancer? Abstracts in Hematology and Oncology, 2005; 8 (2): 3-4.
• Bhoola SM. Studies on psychosocial issues related to genetic susceptibility testing provide insight and stress need for more investigation. Abstracts in Hematology and Oncology, 2005; 8 (3):11-13. 
• Bhoola SM, Alvarez RD, Coleman RL, Herzog T, Morris R, Bryant C, Estes JM. Retrospective analysis of weekly topotecan as salvage therapy in relapsed ovarian cancer. Gynecologic Oncology, 2004; 95(3):564-569.
• LamJT, Kanerva A, Bauerschmitz GJ, Takayama K, Suzuki K, Yamamoto M, Bhoola SM, Liu B, Wang M, Barnes MN, Alvarez RD, Siegal GP, Curiel DT, Hemminki A. Inter-patient variation in efficacy of five oncolytic adenovirus candidates for ovarian cancer therapy. J Gene Med, 2004; 6(12):1333-1342.
• Leath CA III, Straughn JM, Estes JM, Kirby TO, Bhoola SM, Barnes MN III, Kilgore LC, Alvarez RD. The impact of aborted radical hysterectomy in patients with cervical carcinoma. Gynecologic Oncology, 2004; 95(1): 204-207. 
• Bhoola SM, Alvarez RD. Novel Therapies for Recurrent Ovarian Cancer Management. Expert Rev Anticancer Ther, 2004; 4(3):437-448.
• Leath CA, Straughn JM, Bhoola, SM, Partridge EE, Kilgore LC, Alvarez RD. The Role of Radical Parametrectomy in the Treatment of Occult Cervical Carcinoma After Extrafascial Hysterectomy. Gynecologic Oncology, 2004; 92 (1):215-219.
• Bhoola SM, Straughn JM, Shaw DR, Guerrero A, Racelis A, Grizzle W, Alvarez RD, Lim SH, Strong TV. Characterization of sperm protein 17: an apparent tumor growth facilitator and potential target for immunotherapy in ovarian cancer, planned submission
• Straughn JM, Shaw DR, Guerrero A, Bhoola SM, Racelis A, Wang Z, Chiriva- Internati M, Grizzle W, Alvarez RD, Lim SH, Strong TV. Expression of sperm protein 17 (Sp17) in ovarian cancer. Int J. Cancer, 2004; 108(6):805-811.
• Estes JM, Rocconi R, Straughn JM, Bhoola SM, Leath CA, Alvarez RD, Kilgore LC, Huh WK. Complications of indwelling venous access devices in patients with gynecologic malignancies. Gynecologic Oncology, 2003; 91(3): 591-595.
• Barker SD, Coolidge CJ, Kanerva A, Hakkarainen T, Yamamoto M, Liu B, Rivera AA, Bhoola SM, Barnes MN, Alvarez RD, Curiel DT, Hemminki A. The secretory leukoprotease inhibitor (SLPI) promoter for ovarian cancer gene therapy. J Gene Med, 2003; 5:300-310.
• Kanerva a, Wang M, Bauerschmitz J, Lam JT, Desmond RA, Bhoola SM, Barnes M, Alvarez RD, Siegal GP, Curiel DT, Hemminki A. Gene transfer to ovarian cancer versus normal tissues with fiber-modified adenovirus. Molecular Therapy 2002; 5:695-704.
• Umpierrez GE, Digirolamo M, Tuvlin JA, Isaacs SD, Bhoola SM, Kokko JP. Differences in metabolic and hormonal milieu in diabetic-and-alcohol-induced ketoacidosis. Journal of Critical Care 2000; 15:52-59.
• Bhoola SM, DeRose PB, Cohen C. Ductal carcinoma of the breast: frequency of biochemical markers according to histologic subtype. Applied Immunohistochemistry and Molecular Morphology, 1999; 7(2):108-115.
• Mendez LE, Bhoola SM, Horowitz IR. Bilateral tubo-ovarian abscesses four years after total abdominal hysterectomy. Infect Dis Obstet Gynecol 1998; 6:138-140.